Some oral hypoglycemic agents, such as Glyburide, Rosiglitazone, and Repaglinide, are mainly metabolized by CYP2C8 or CYP2C9, it may increase hypoglycemia risk when those medicines are used together with SDEA. This evidence concerns the gene CYP2C9 and Hypoglycemia.